226 results on '"Mirtti T"'
Search Results
2. PI-RADS score 5 is a strong predictor for rapid prostate cancer specific death
3. Negative MRI rules out clinically significant prostate cancer regardless of PI-RADS era
4. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
5. Gene expression in multi-parametric MRI-visible and invisible prostate cancers is associated with progression
6. The spatial landscape of clonal somatic mutations in benign and malignant prostate epithelia
7. The spatial landscape of clonal somatic mutations in benign and malignant prostate epithelia
8. Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers
9. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion
10. Tekoäly patologian kudosleikkeiden tulkinnassa
11. 80P Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples
12. Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models
13. Biomarker accompanied significance of mpMRI-visible and invisible lesions for adverse pathology and biochemical recurrence after radical prostatectomy
14. Expected impact of MRI related interreader variability on ProScreen prostate cancer screening trial
15. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas
16. A population-based randomized trial of early detection of clinically significant prostate cancer (ProScreen): Pilot phase results
17. Stat5 mediates enzalutamide-resistant prostate cancer growth
18. 793 - The spatial distribution of positive cores predicts outcomes of active surveillance in very low risk prostate cancer patients
19. 795 - PTEN status in diagnostic biopsies predicts active surveillance rebiopsy Gleason upgrade, treatment change and adverse surgical histopathological findings
20. SPCG-15 : a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
21. SPCG-15:a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
22. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
23. Positive status for STAT5 locus amplification in conjunction with STAT5 protein expression is a powerful predictor of recurrence after radical prostatectomy
24. Prostate cancer active surveillance: Longitudinal health-related quality of life, IPSS and IIEF changes in the Finnish arm of the prospective PRIAS study with up to nine-years of follow-up
25. Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment
26. Precision systems medicine in urological Tumors – Molecular profiling and functional testing
27. The spatial distribution of positive cores predicts outcomes of active surveillance in very low risk prostate cancer patients
28. PTEN status in diagnostic biopsies predicts active surveillance rebiopsy Gleason upgrade, treatment change and adverse surgical histopathological findings
29. Utilization of next-generation sequencing techniques to investigate markers for chemosensitivity in bladder cancer patients treated with neoadjuvant chemotherapy prior to radical cystectomy
30. 1135 - A population-based randomized trial of early detection of clinically significant prostate cancer (ProScreen): Pilot phase results
31. 995 - Stat5 mediates enzalutamide-resistant prostate cancer growth
32. Performance of serial multiparametric MRI among the Finnish arm of the PRIAS active surveillance cohort of patients with Gleason 3+3 prostate cancer
33. Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy
34. Association of angiopoietin-2 and Ki-67 expression with vascular density and sunitinib response in metastatic renal cell carcinoma
35. Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy
36. 101 - Positive status for STAT5 locus amplification in conjunction with STAT5 protein expression is a powerful predictor of recurrence after radical prostatectomy
37. 66 - Prostate cancer active surveillance: Longitudinal health-related quality of life, IPSS and IIEF changes in the Finnish arm of the prospective PRIAS study with up to nine-years of follow-up
38. Identification of novel therapeutic strategies to target ERG oncogene positive prostate cancer
39. High-throughput compound and siRNA screening to identify novel treatment options for ERG oncogene positive prostate cancers
40. High-throughput screening for novel prostate cancer drug targets
41. 3 - Precision systems medicine in urological Tumors – Molecular profiling and functional testing
42. 525 - Utilization of next-generation sequencing techniques to investigate markers for chemosensitivity in bladder cancer patients treated with neoadjuvant chemotherapy prior to radical cystectomy
43. P155 Loss of PTEN expression together with ERG overexpression leads to shorter disease-specific survival in prostate cancer after radical prostatectomy
44. Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept
45. 273: Androgen receptor interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions
46. 684: Helsinki Urological Biobank (HUB): A new-generation integrated biobank for facilitating precision medicine and translational research in urological cancers
47. 412 Pathological validation of adjuvant anti-fibroblast growth factor receptor 3 (FGFR3) treatment for bladder cancer
48. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
49. 851 - Association of angiopoietin-2 and Ki-67 expression with vascular density and sunitinib response in metastatic renal cell carcinoma
50. 37 - Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.